Resveratrol analogues surprisingly effective against triple‑negative breast cancer, independent of ERα

  • Authors:
    • Xylia J. Horgan
    • Hannah Tatum
    • Emily Brannan
    • Daniel H. Paull
    • Lyndsay V. Rhodes
  • View Affiliations

  • Published online on: April 16, 2019     https://doi.org/10.3892/or.2019.7122
  • Pages: 3517-3526
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Resveratrol, a plant‑derived stilbene compound, has exhibited anticancerous properties, including breast cancer. Stilbenes have a molecular structure highly similar to estrogen and have the ability to bind estrogen receptors and regulate activity. Numerous studies have demonstrated the effectiveness of resveratrol in estrogen receptor‑positive (ER‑positive) subtypes of breast cancer, yet the effects in ER‑negative subtypes, including triple‑negative breast cancer (TNBC), have been limited. In the present study, resveratrol and 28 analogues were tested on a panel of ER‑positive and TNBC cell lines to determine effects on cell viability. Several compounds exhibited significant impacts on cell viability and suggested changes in cell morphology, with high potency of select compounds compared to resveratrol observed in a dose‑dependent manner. Due to the lack of estrogen receptors in TNBC and the estrogenic nature of stilbenes, regulation of breast cancer‑associated cellular pathways was assessed for five analogues shown to significantly inhibit cell viability. Top regulated pathways included apoptosis (confirmed by caspase assay) and DNA damage repair. Overall, our results indicated several resveratrol analogues to be active in ER‑negative phenotypes, acting through an ER receptor‑independent manner, supporting further investigation into their mechanism of action and use as potential chemotherapeutics in higher‑risk breast cancer cases.

References

1 

DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Chavez KJ, Garimella SV and Lipkowitz S: Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32:35–48. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Rajappa S, Bajpai J, Basade M, Ganvir M, Goswami C, Murali A, Rathi AK, Kaushal V, Jain S, Parikh PM, et al: Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer. South Asian J Cancer. 7:137–141. 2018. View Article : Google Scholar : PubMed/NCBI

4 

Alfarsi L, Johnston S, Liu DX, Rakha E and Green AR: Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. Histopathology. 73:545–558. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Bowers JL, Tyulmenkov VV, Jernigan SC and Klinge CM: Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology. 141:3657–3667. 2000. View Article : Google Scholar : PubMed/NCBI

6 

Lu R and Serrero G: Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol. 179:297–304. 1999. View Article : Google Scholar : PubMed/NCBI

7 

Sirerol JA, Rodríguez ML, Mena S, Asensi MA, Estrela JM and Ortega AL: Role of natural stilbenes in the prevention of cancer. Oxid Med Cell Longev. 2016:31289512016. View Article : Google Scholar : PubMed/NCBI

8 

Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, Bishayee A and Ahn KS: The role of resveratrol in cancer therapy. Int J Mol Sci. 18:25892017. View Article : Google Scholar :

9 

Hsieh TC, Wong C, John Bennett D and Wu JM: Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: An in silico and biochemical approach targeting integrin αvβ3. Int J Cancer. 129:2732–2743. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Yenugonda VM, Kong Y, Deb TB, Yang Y, Riggins RB and Brown ML: Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells. Cancer Biol Ther. 13:925–934. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Lee PS, Chiou YS, Ho CT and Pan MH: Chemoprevention by resveratrol and pterostilbene: Targeting on epigenetic regulation. Biofactors. 44:26–35. 2018. View Article : Google Scholar : PubMed/NCBI

12 

Chin YT, Hsieh MT, Yang SH, Tsai PW, Wang SH, Wang CC, Lee YS, Cheng GY, HuangFu WC, London D, et al: Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. Oncotarget. 5:12891–12907. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Liu Y, Liu Y, Chen H, Yao X, Xiao Y, Zeng X, Zheng Q, Wei Y, Song C, Zhang Y, et al: Synthetic resveratrol derivatives and their biological activities: A review. Open J Med Chem. 05:97–105. 2015. View Article : Google Scholar

14 

Walle T: Bioavailability of resveratrol. Ann NY Acad Sci. 1215:9–15. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Licznerska B, Szaefer H, Wierzchowski M, Mikstacka R, Papierska K and Baer-Dubowska W: Evaluation of the effect of the new methoxy-stilbenes on expression of receptors and enzymes involved in estrogen synthesis in cancer breast cells. Mol Cell Biochem. 444:53–62. 2018. View Article : Google Scholar : PubMed/NCBI

16 

Jo SJ, Park PG, Cha HR, Ahn SG, Kim MJ, Kim H, Koo JS, Jeong J, Park JH, Dong SM, et al: Cellular inhibitor of apoptosis protein 2 promotes the epithelial-mesenchymal transition in triple-negative breast cancer cells through activation of the AKT signaling pathway. Oncotarget. 8:78781–78795. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Paul S, Mizuno CS, Lee HJ, Zheng X, Chajkowisk S, Rimoldi JM, Conney A, Suh N and Rimando AM: In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer. Eur J Med Chem. 45:3702–3708. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Mizuno CS, Ma G, Khan S, Patny A, Avery MA and Rimando AM: Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha. Bioorg Med Chem. 16:3800–3808. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S and Tolomeo M: Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem. 46:3546–3554. 2003. View Article : Google Scholar : PubMed/NCBI

21 

Pettit GR, Grealish MP, Jung MK, Hamel E, Pettit RK, Chapuis JC and Schmidt JM: Antineoplastic agents. 465. Structural modification of resveratrol: Sodium resverastatin phosphate. J Med Chem. 45:2534–2542. 2002. View Article : Google Scholar : PubMed/NCBI

22 

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME and Collins-Burow BM: Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 14:R792012. View Article : Google Scholar : PubMed/NCBI

23 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Sauter ER: Breast cancer prevention: Current approaches and future directions. Eur J Breast Health. 14:64–71. 2018.PubMed/NCBI

25 

Saluzzo J, Hallman KM, Aleck K, Dwyer B, Quigley M, Mladenovik V, Siebert AE and Dinda S: The regulation of tumor suppressor protein, p53, and estrogen receptor (ERα) by resveratrol in breast cancer cells. Genes Cancer. 7:414–425. 2016.PubMed/NCBI

26 

Leon-Galicia I, Diaz-Chavez J, Albino-Sanchez ME, Garcia-Villa E, Bermudez-Cruz R, Garcia-Mena J, Herrera LA, García-Carrancá A and Gariglio P: Resveratrol decreases Rad51 expression and sensitizes cisplatin-resistant MCF-7 breast cancer cells. Oncol Rep. 39:3025–3033. 2018.PubMed/NCBI

27 

Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR and Bishop DK: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem. 275:23899–23903. 2000. View Article : Google Scholar : PubMed/NCBI

28 

De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, Tramontano D, Fuqua SA and Andò S: Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 25:3695–3707. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Ronghe A, Chatterjee A, Bhat NK, Padhye S and Bhat HK: Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells. Oncotarget. 7:51747–51762. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Ronghe A, Chatterjee A, Singh B, Dandawate P, Murphy L, Bhat NK, Padhye S and Bhat HK: Differential regulation of estrogen receptors α and β by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog. J Steroid Biochem Mol Biol. 144:500–512. 2014. View Article : Google Scholar : PubMed/NCBI

31 

Chin YT, Yang SH, Chang TC, Changou CA, Lai HY, Fu E, HuangFu WC, Davis PJ, Lin HY and Liu LF: Mechanisms of dihydrotestosterone action on resveratrol-induced antiproliferation in breast cancer cells with different ERα status. Oncotarget. 6:35866–35879. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Simoni D, Roberti M, Invidiata FP, Rondanin R, Baruchello R, Malagutti C, Mazzali A, Rossi M, Grimaudo S, Capone F, et al: Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells. J Med Chem. 44:2308–2318. 2001. View Article : Google Scholar : PubMed/NCBI

33 

Kumar A, Rimando AM and Levenson AS: Resveratrol and pterostilbene as a microRNA-mediated chemopreventive and therapeutic strategy in prostate cancer. Ann NY Acad Sci. 1403:15–26. 2017. View Article : Google Scholar : PubMed/NCBI

34 

Moon D, McCormack D, McDonald D and McFadden D: Pterostilbene induces mitochondrially derived apoptosis in breast cancer cells in vitro. J Surg Res. 180:208–215. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Hong YB, Kang HJ, Kim HJ, Rosen EM, Dakshanamurthy S, Rondanin R, Baruchello R, Grisolia G, Daniele S and Bae I: Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Exp Mol Med. 41:151–160. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Horgan, X.J., Tatum, H., Brannan, E., Paull, D.H., & Rhodes, L.V. (2019). Resveratrol analogues surprisingly effective against triple‑negative breast cancer, independent of ERα. Oncology Reports, 41, 3517-3526. https://doi.org/10.3892/or.2019.7122
MLA
Horgan, X. J., Tatum, H., Brannan, E., Paull, D. H., Rhodes, L. V."Resveratrol analogues surprisingly effective against triple‑negative breast cancer, independent of ERα". Oncology Reports 41.6 (2019): 3517-3526.
Chicago
Horgan, X. J., Tatum, H., Brannan, E., Paull, D. H., Rhodes, L. V."Resveratrol analogues surprisingly effective against triple‑negative breast cancer, independent of ERα". Oncology Reports 41, no. 6 (2019): 3517-3526. https://doi.org/10.3892/or.2019.7122